An audit of hospital based outpatient infusions and a pilot program of community-based monoclonal antibody infusions

摘要

Introduction Infliximab, a chimeric monoclonal antibody to tumour necrosis factor alpha, is administered as an intravenous infusion requiring a costly hospital day case or inpatient admission.